We are live on ! Find out more
GPP

Great Point Partners Portfolio holdings

AUM $435M
1-Year Est. Return 318.81%
This Fund
S&P 500
This Quarter Est. Return
-4.54%
1 Year Est. Return
+318.81%
3 Year Est. Return
+553.97%
5 Year Est. Return
+856.21%
10 Year Est. Return
+18,148.08%
AUM
$487M
AUM Growth
+$94.7M
Cap. Flow
+$118M
Cap. Flow %
24.18%
Top 10 Hldgs %
60.21%
Holding
43
New
8
Increased
15
Reduced
5
Closed
8

Top Buys

Rank Stock Value
1
TXMD icon
TherapeuticsMD
TXMD
+$20.3M
2
GBT
Global Blood Therapeutics, Inc.
GBT
+$17.6M
3
TRVN
Trevena, Inc.
TRVN
+$17.2M
4
NBIX icon
Neurocrine Biosciences
NBIX
+$16.1M
5
MACK
Merrimack Pharmaceuticals, Inc.
MACK
+$13.9M

Top Sells

Rank Stock Value
1
DERM
Dermira, Inc.
DERM
+$18.2M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$11.2M
3
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$7.57M
4
PLXP
PLx Pharma Inc. Common Stock
PLXP
+$2.59M
5
PDLI
PDL BioPharma, Inc.
PDLI
+$2.16M

Sector Composition

Rank Sector Weight
1 Healthcare 81.16%
2 Technology 1.42%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ADMS
1
DELISTED
Adamas Pharmaceuticals
ADMS
$44M 9.03%
2,601,351
– –
FOMX
2
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$33.3M 6.84%
3,000,000
+230,575
+8% +$2.17M
VNDA icon
3
Vanda Pharmaceuticals
VNDA
$307M
$32.1M 6.59%
2,010,000
-696,134
-26% -$11.2M
SGYP
4
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
$30.3M 6.22%
4,973,509
-1,448,723
-23% -$7.57M
ZGNX
5
DELISTED
Zogenix, Inc.
ZGNX
$29.7M 6.09%
2,440,959
– –
NBIX icon
6
Neurocrine Biosciences
NBIX
$16.8B
$29M 5.96%
750,000
+355,920
+90% +$16.1M
ENTA icon
7
Enanta Pharmaceuticals
ENTA
$366M
$27.7M 5.7%
828,253
+38,253
+5% +$1.1M
MDCO
8
PUT
DELISTED
Medicines Co
MDCO
$25.5M 5.23%
+750,000
New +$26.6M
RXDX
9
DELISTED
Ignyta, Inc.
RXDX
$21.2M 4.36%
4,000,000
+524,773
+15% +$3.06M
MACK
10
DELISTED
Merrimack Pharmaceuticals, Inc.
MACK
$20.4M 4.19%
635,500
+325,102
+105% +$13.9M
AVXS
11
DELISTED
AveXis, Inc. Common Stock
AVXS
$19.7M 4.05%
413,179
+32,084
+8% +$1.71M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$19.7M 4.05%
385,683
+120,790
+46% +$5.69M
TXMD icon
13
TherapeuticsMD
TXMD
$23.5M
$18.9M 3.88%
+65,520
New +$20.3M
TRVN
14
DELISTED
Trevena, Inc.
TRVN
$17.6M 3.62%
+4,801
New +$17.2M
CLCD
15
DELISTED
CoLucid Pharmaceuticals, Inc.
CLCD
$15.9M 3.27%
437,865
+37,865
+9% +$1.34M
GBT
16
DELISTED
Global Blood Therapeutics, Inc.
GBT
$14.4M 2.97%
+1,000,000
New +$17.6M
DBVT
17
DBV Technologies
DBVT
$799M
$13M 2.67%
37,000
+23,855
+181% +$8.57M
APYX icon
18
Apyx Medical
APYX
$173M
$11M 2.25%
3,055,000
+375,000
+14% +$1.67M
RCKT icon
19
Rocket Pharmaceuticals
RCKT
$340M
$9.15M 1.88%
375,000
+351,481
+1,494% +$10M
ACAD icon
20
Acadia Pharmaceuticals
ACAD
$4.43B
$7.79M 1.6%
+270,000
New +$7.14M
CNXR
21
DELISTED
Connecture, Inc.
CNXR
$6.93M 1.42%
4,127,232
– –
VIRX
22
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$5.57M 1.14%
43,939
+13,551
+45% +$1.89M
BCRX icon
23
PUT
BioCryst Pharmaceuticals
BCRX
$2.28B
$4.59M 0.94%
725,000
– –
MYOV
24
DELISTED
Myovant Sciences Ltd.
MYOV
$4.35M 0.89%
+350,000
New +$4.06M
MRTX
25
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$4.13M 0.85%
870,261
+642,604
+282% +$3.5M
1
2

Similar funds

GDS
Gimbel Daniel Scott $435M AUM 78.68% 1-Year Est. Return
JWM
JPL Wealth Management Highlands Ranch, Colorado $435M AUM 16.48% 1-Year Est. Return
SWG
Summit Wealth Group White River Junction, Vermont $436M AUM 13.96% 1-Year Est. Return
SCP
Seafarer Capital Partners Larkspur, California $436M AUM 42.05% 1-Year Est. Return
VIM
VELA Investment Management New Albany, Ohio $436M AUM 15.16% 1-Year Est. Return
VDBMI
Van Den Berg Management I Austin, Texas $436M AUM 40.66% 1-Year Est. Return
ACG
Anchorage Capital Group New York $436M AUM 38.51% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM

Great Point Partners's Q4 2016 Portfolio in Review

As of Q4 2016, Great Point Partners held 43 positions worth $487M, up 24% from $392M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Great Point Partners deployed $118M of net new capital in Q4 2016, opening 8 new positions and adding to 15 existing holdings. Its largest new stake was TherapeuticsMD: 65,520 shares worth $18.9M.

By sector, the portfolio is most concentrated in Healthcare at 81% of assets, up from 77% a quarter earlier, followed by Technology.

On the sell side, the largest reduction was Dermira, Inc., an estimated $18.2M trimmed.

  • Great Point Partners's largest Q4 2016 buy was TherapeuticsMD: 65,520 shares worth $18.9M.
  • Great Point Partners added most to Neurocrine Biosciences in Q4 2016, an estimated $16.1M increase.
  • Great Point Partners's biggest Q4 2016 reduction was Dermira, Inc., cutting an estimated $18.2M.
  • Great Point Partners fully exited PLx Pharma Inc. Common Stock in Q4 2016, selling an estimated $2.59M.
  • Great Point Partners's ten largest holdings make up 60% of its $487M portfolio in Q4 2016.
  • Great Point Partners opened 8 new positions and closed 8 in Q4 2016.
  • Great Point Partners's portfolio value rose 24% quarter-over-quarter to $487M.

Based on Great Point Partners's 13F filing for Q4 2016, filed 14 Feb 2017.